Rick Panicucci

MaveriX Oncology, Inc. operates as a a biotechnology company. It focuses on the discovery, development, and commercialization of targeted small molecule cancer chemo-immunotherapies. The company was founded by Steven A. Everett and Craig Alan Coburn in 2015 and is headquartered in Palo Alto, CA.

Part of BridgeBio Pharma, Inc., QED Therapeutics, Inc. is a biotechnology company based in Palo Alto, CA. The private company focuses on precision medicine for FGFR-driven diseases and is committed to finding solutions to FGFR-driven cancers and diseases to give patients more possibilities. QED Therapeutics' lead investigational candidate is infigratinib, an orally administered, FGFR1-3 selective tyrosine kinase inhibitor that has shown activity in patients with chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions and advanced urothelial carcinoma with FGFR3 genomic alterations. In 2020, QED submitted a new drug application (NDA) with the Food and Drug Administration for second- and later-line cholangiocarcinoma. Michael Henderson has been the CEO of the company since 2017.

BridgeBio Pharma LLC engages in the discovery and development of pharmaceutical drugs for patients with genetic diseases. It offers transthyretin stabilizer, SHP2 inhibitor, KRAS inhibitor, Collagen 7 replacement, and S1P-lyase inhibitor. The company was founded by Neil Kumar and is headquartered in Palo Alto, CA.

Part of BridgeBio Pharma, Inc., Origin Biosciences, Inc. is an actively managed investment issuer focused on making equity investments in psychedelics industry-related companies to provide investors with diverse exposure to the sector. The private company is based in Palo Alto, CA. The company, led by a team of industry experts, leverages its management expertise, professional network, and due diligence process to identify and invest in leading and emerging companies focused on the emerging psychedelics sector. Michael Henderson has been the CEO of the company since 2018.

Wuxi Apptec, Inc. provides pharmaceutical and biotechnology services. Its services include discovery, lab testing division, small molecule pharmaceutical development and manufacturing international discovery service unit, WuXi biologics, chemistry, bioanalytical, clinical & regulatory, genome center, biological reagents and WuXi venture fund. The company was founded by Ge Li in December 2000 and is headquartered in St. Paul, MN.